J. Seidel

Oncology · with Kabashima · 2018

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom J. Seidel trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. E. Wherry
  2. Antoni Ribas

Papers from J. Seidel's perspective

Ordered by how strongly the researchers J. Seidel trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  2. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell)
  3. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (Journal of Experimental Medicine)
  4. PD-1 blockade induces responses by inhibiting adaptive immune resistance (Nature)
  5. T cell exhaustion (Nature Immunology)
  6. PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
  7. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma (New England Journal of Medicine)
  8. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 (Journal of Immunology)
  9. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. (New England Journal of Medicine)
  10. PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)

Their papers